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Abstract
Human immunodeficiency virus (HIV) infection has frequently been associated with vitamin D deficiency as
well as chronic inflammatory response. We tested the hypothesis of an independent relationship between serum
concentrations of 25-hydroxyvitamin D [25(OH)D] and high-sensitivity C-reactive protein (CRP) in a cohort of
HIV-positive people. A cross-sectional survey was conducted among 316 HIV-positive people (181 men and 135
women) aged 16 to 60 years residing in the Kathmandu Valley, Nepal. Serum high-sensitivity CRP concentra-
tions and serum 25(OH)D levels were measured by the latex agglutination nephelometry method and the
competitive protein-binding assay, respectively. The relationship between serum CRP concentrations and
25(OH)D serum level was assessed using multiple logistic regression analysis with adjustment of potential
cardiovascular and HIV-related factors. The proportions of participants with 25(OH)D serum levels < 20 ng/ml,
20–30 ng/ml, and ‡ 30 ng/ml were 83.2%, 15.5%, and 1.3%, respectively. The mean 25(OH)D serum levels in
men and women were 15.3 ng/ml and 14.4 ng/ml, respectively. Participants with a 25(OH)D serum level of
< 20 ng/ml had a 3.2-fold higher odds of high CRP ( > 3mg/liter) compared to those with a 25(OH)D serum level
of ‡ 20 ng/ml ( p = 0.005). Men and women with a 25(OH)D serum level of < 20 ng/ml had 3.2- and 2.7-fold
higher odds of high CRP (> 3mg/liter), respectively, compared to those with a 25(OH)D serum level of ‡ 20ng/ml.
The relationships remained significant only in men ( p = 0.02) but not in women ( p= 0.28). The risk of having a high
level of inflammation (CRP> 3mg/liter) may be high among HIV-positive men and women with a 25(OH)D serum
level of < 20ng/ml.
Introduction
Inflammation is a key process in human immunodefi-ciency virus (HIV) infection.1–4 HIV infection may
activate inflammatory pathways through activating endo-
thelium by secreting cytokines in response to mononuclear or
adventitial cell activation by the virus or by the direct effect of
the secreted HIV-associated proteins gp120 (envelope glyco-
protein) and tat (transactivator of viral replication) on endo-
thelium.1 One of the bioactive molecules that may mediate the
systemic effects of HIV infection includes high-sensitivity
C-reactive protein (CRP), a proinflammatory biomarker. CRP
has been associated with parameters of disease progression,
such as CD4 cell count andHIVviral load, aswell as a decreased
time to AIDS5 and it is an independent predictor of survival.6
A low vitamin D level has been observed in people infected
with HIV. Accordingly, a number of studies have revealed
higher rates of vitamin D deficiency among HIV-positive
people.7–9 In recent studies, low levels of vitamin D were
related to disease progression of HIV/AIDS and its compli-
cations.10,11 The causes of this deficiency are not known
but might include a defect in renal 1a-hydroxylation of
25-hydroxyvitamin D3 mediated by proinflammatory cyto-
kines12 or by the intake of antiretroviral drugs.13,14 Thus, the
1Waseda Institute for Advanced Study, Waseda University, Tokyo, Japan.
2Department of Public Health, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst,
Massachusetts.
3School of Community and Global Health, Claremont Graduate University, Claremont, California.
4Department of Community and Global Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
5Department of International Medical Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.
6Graduate School of International Health Development, Nagasaki University, Nagasaki, Japan.
AIDS RESEARCH AND HUMAN RETROVIRUSES
Volume 29, Number 3, 2013
ª Mary Ann Liebert, Inc.
DOI: 10.1089/aid.2012.0120
528
literature suggests that HIV-positive people have low vitamin
D levels as well as chronic inflammation.
Vitamin D deficiency has been reported as a risk factor for
inflammation and inflammatory diseases in populations other
than HIV-positive people.15–17 Vitamin D deficiency increases
systemic inflammation as documented by elevated levels of
CRP.18,19 The immunomodulating effects of vitamin D may
explain the reported epidemiological associations between
vitamin D status and inflammation.15 Mechanistically, vita-
min D down-regulates the activation of nuclear factor-jB, an
important regulator of genes encoding for several inflamma-
tory cytokines.20 In addition, vitamin D diminishes the pro-
duction by macrophages of proinflammatory cytokines and
chemokines that may interfere with systemic inflammation.21
Nevertheless, the association between vitamin D status and
systemic inflammation in HIV-positive people has not been
investigated to the best of our knowledge. In this study, we
aim to assess the relationship between serum concentrations
of 25-hydroxyvitaminD [25(OH)D] levels andCRP in a cohort
of HIV-positive people.
Materials and Methods
Study design and setting
This cross-sectional survey was conducted among HIV-
positive people living in the Kathmandu Valley, Nepal during
February and March 2010 in the wider context of the baseline
survey of a longitudinal healthy living intervention headed by
the first and second authors. All HIV-positive peoplewhowere
in contact with five local nongovernmental organizations
(NGOs) working within HIV-positive communities in the
Kathmandu Valley were invited to participate in the study.
The Kathmandu Valley comprises three districts (Kath-
mandu, Lalitpur, and Bhaktapur) with an estimated popula-
tion of 2.2 million.22 Of Nepal’s estimated 70,000 HIV-positive
people aged 15–49 years,23 15.7% were living in the Kath-
mandu Valley at the end of 2006.24 Nepal has been facing an
escalating, concentrated epidemic of HIV/AIDS with preva-
lence especially high among injecting drug users (IDUs).23
The HIV prevalence among IDUs living in the capital city of
Kathmandu was 34.8% in 2007.25
Study participants
The 322 HIV-positive people, whowere in contact with five
NGOs working within HIV-positive communities, partici-
pated in the study. All participants were adults from 16 to 60
years of age with a self-reported diagnosis of HIV-positive
status, and gave their written informed consent to participate.
Participants who had no information on serum CRP concen-
tration or 25(OH)D serum levels or sociodemographic or an-
thropometric information were excluded, resulting in a final
study population of 316 participants (181 men and 135
women). The study protocol conformed to the ethical guide-
lines of the 1975 Declaration of Helsinki andwas approved by
the Ethics Committee of the Nepal Health Research Council,
Kathmandu, Nepal, National Center for Global Health and
Medicine, Japan, and Waseda University, Tokyo, Japan.
Interview data
Data were collected by means of personal interviews. We
used the structured pretested Nepali language questionnaire
to collect the information. Trained interviewers administered
the questionnaire face-to-face in a private setting with each
interview lasting approximately 45–60min. We used a pre-
pared information sheet to inform all participants about the
study procedures.We requested participants to sign informed
consent forms prior to being interviewed. Interviewers re-
assured participants that numerical codes would be used in
place of names in all records to ensure confidentiality.
Trained interviewers collected information from HIV-
positive participants on demographics, 24-h dietary intake,
HIV-related clinical events, and therapy. The antiretroviral
therapy was measured by participants’ current use of medi-
cine at the time of the survey along with specified duration
and names of medication and adherence. Alcohol consump-
tion and smoking status were categorized as never and ever
been drinking and smoking, respectively. From the reported
years of formal education, we categorized education into
never or ever been to school. Similarly, from the reported
specific types of work, we categorized occupation into yes or
nowork. Physical activitywas assessed in average hours spent
per day in the past 12 months on common physical activities
on the basis of the usual frequency and duration of two dif-
ferent activities (walking and any types of mild, moderate, or
hard laborwork). The past history of any diseasewas asked by
the question ‘‘In the past 12 months, did you suffer from any
type of diseases including minor illnesses?’’ with a response of
yes or no. If the response was yes, the signs or symptoms of
disease or disease diagnosis with details of health-seeking
behavior and treatment of each disease were inquired about.
Laboratory methods
Blood sampleswere obtained from 322 participants after an
overnight fast during the survey period. Ten milliliters of
venous blood was drawn into an evacuated tube and centri-
fuged immediately for 15min, after which the serum samples
were placed in a cooler box and transported to a laboratory.
The separated serum was stored in three tubes (2.0ml, 1.5ml,
and 1.5ml) and was stored at - 80C until analysis. One tube
of 2.0ml was sent to an external laboratory (Mitsubishi
Chemical Medience Corporation, Tokyo, Japan) for testing,
where high-sensitivity serum CRP concentrations were mea-
sured by the latex agglutination nephelometry method and
the 25(OH)D serum level was measured by the competitive
protein-binding assay. The intraassay coefficient of variation
at CRP levels of 0.09mg/liter and 1.45mg/liter was 5.0 and
1.7%, respectively. The intraassay coefficient of variation of
vitamin D was 10.93 and 7.70%, respectively. The blood
sample of all the study participants was drawn from mid-
February to mid-March. Therefore the timing of blood sample
collection may not have a significant effect on either serum
25(OH)D or serum CRP levels.
Measurements of total cholesterol, low-density lipoprotein
(LDL) cholesterol, high-density lipoprotein (HDL) cholesterol,
and triglycerides were assessed by the enzymatic colorimetric
method. The interassay coefficient of variation at total cho-
lesterol levels of 125.48mg/dl, 166.93mg/dl, and 238.32mg/
dl was 1.24, 1.09, and 0.97%, respectively. The intraassay co-
efficient of variation at total cholesterol levels of 127.77mg/dl,
169.90mg/dl, and 241.04mg/dl was 0.67, 0.62, and 0.77%,
respectively. The interassay coefficient of variation at
LDL cholesterol levels of 75.54mg/dl, 106.17mg/dl, and
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116.86mg/dl was 1.32, 1.20, and 1.24%, respectively. The in-
traassay coefficient of variation at LDL cholesterol levels of
74.47mg/dl, 104.96mg/dl, and 118.20mg/dl was 0.82, 0.58,
and 0.66%, respectively. The interassay coefficient of variation
at HDL cholesterol levels of 33.97mg/dl, 44.97mg/dl, and
57.38mg/dl was 1.01, 1.25, and 1.04%, respectively. The in-
traassay coefficient of variation at HDL cholesterol levels of
34.50mg/dl, 45.98mg/dl, and 59.52mg/dl was 0.73, 0.49,
and 0.80%, respectively. The interassay coefficient of variation
at triglyceride levels of 47.50mg/dl, 80.63mg/dl, and
98.98mg/dl was 1.70, 1.31, and 1.35%, respectively. The in-
traassay coefficient of variation at triglyceride levels
of 47.71mg/dl, 79.90mg/dl, and 109.13mg/dl was 0.92,
0.70, and 0.67%, respectively. CD4 cell counts were deter-
mined using a specificmonoclonal antibody and fluorescence-
activated cell sorter (FACS) analysis. The viral load
measurement was not done due to lack of resources.
Physical examination
Body height and weight were measured while the partici-
pants were fasting overnight and wearing light clothing
without shoes. The weight was measured in kilograms on a
digital scale and the height was measured in centimeters by a
stadiometer. Body mass index (BMI) was calculated as body
weight in kilograms divided by the square of body height in
meters. Waist circumference was taken without outer cloth-
ing, using a tape measure in light contact with but not com-
pressing the skin. It wasmeasured at the level of the umbilicus
region at the end of normal expiration while participants were
standing. Blood pressure was measured with the Omron
Automatic Blood Pressure Monitor after the participants had
been seated for at least 10min with his or her feet on the floor
and his or her arms supported at heart level. Two indepen-
dent measurements were done to estimate mean values for all
parameters.
Statistical analyses
The t test and the chi-square test were used to assess the
demographic, lifestyle, anthropometric, and 25(OH)D serum
level difference, between the cutoff value of 25(OH)D serum
level of < 20 ng/ml and ‡ 20 ng/ml, for continuous variables
and categorical variables, respectively. This cutoff value was
utilized because the literature defines vitamin D deficiency as
a 25(OH)D serum level of < 20 ng/ml (50 nmol/liter).26
The relationship between serum CRP concentrations and
25(OH)D serum level was assessed using multiple logistic
regression analysis. CRP was studied as a categorical variable
based on the Center for Disease Control/American Heart
Association guidelines of high risk as CRP > 3mg/liter.27
Therefore the serum CRP concentrations were categorized
into high (CRP > 3mg/liter) and not high (CRP £ 3mg/liter).
The odds ratios and 95% CIs for high CRP were calculated for
each category of 25(OH)D serum level. Major socio-
demographic characteristics and other mediators having
previously established or theoretically feasible associations
with the dependent variable were included as covariates or
potential confounders in the analyses. The age (years, con-
tinuous), sex (men or women), marital status (married or
unmarried/separated), education (never or ever been to
school), occupation (yes or no), alcohol intake (never or
ever), smoking (never or ever), physical activity (£ 3.5 or
> 3.5 h/day), bodymass index (kg/m2, continuous), history of
any disease in the past 12 months including minor illnesses
(yes or no), systolic blood pressure (mm Hg, continuous),
cholesterol (mg/dl, continuous), triglycerides (mg/dl, con-
tinuous), CD4 + T cell count ( £ 200 or > 200; cells/ll), duration
of antiretroviral therapy (ART) (no, 0–12, 13–24, 25–36, > 36
months), and efavirenz exposure (yes or no) were adjusted for
in the multivariate model. The multiple linear regression
analysis was performed between serum CRP concentrations
and serum 25(OH)D level. To better approximate normal
distributions, serum CRP concentrations were log-trans-
formed prior to analysis. All p values were two-sided and p
values less than 0.05 were considered statistically significant.
Analyses were performed with SAS statistical software ver-
sion 9.1 (SAS Institute, Inc., Cary, NC).
Results
The proportions of participants with a 25(OH)D serum le-
vel of < 20 ng/ml, 20–30 ng/ml, and > 30 ng/ml were 83.2%,
15.5%, and 1.3%, respectively. The means (SD) of 25(OH)D
serum levels in men and women were 15.3 (6.24) and 14.4
(4.71), respectively.
Demographic and clinical characteristics of the 316 HIV-
positive participants by 25(OH)D serum level of < 20 ng/ml
and ‡ 20 ng/ml are shown in Table 1. HIV-positive partici-
pants with a 25(OH)D serum level of < 20 ng/ml were female
more thanmale; a higher proportion was taking antiretroviral
therapy, had a lower mean BMI, and had a lower total
mean cholesterol than those with a 25(OH)D serum level of
‡ 20 ng/ml. The exposure to antiretroviral therapy (ART) such
as nevirapine, efavirenz, tenofovir, and nucleoside reverse
transcriptase inhibitors (NRTIs) was not significantly associ-
ated with a 25(OH)D serum level of < 20ng/ml/‡ 20ng/ml.
The association of the 25(OH)D serum level with high in-
flammation is shown in Table 2. HIV-positive participants
with a 25(OH)D serum level of < 20 ng/ml had a higher
proportion of high CRP ( > 3mg/liter) of 33.5% compared
with 17% in those with a 25(OH)D serum level of ‡ 20 ng/ml
(Table 2). After adjustment for demographic, anthropometric,
lifestyle, and HIV-related factors, those with a 25(OH)D se-
rum level of < 20 ng/ml had a 3.2-fold higher odds of high
CRP (> 3mg/liter) compared to those with a 25(OH)D serum
level of ‡ 20 ng/ml ( p= 0.005). The multiple linear regression
analysis also showed an inverse relationship between serum
CRP concentrations and 25(OH)D serum level (b = - 0.03;
p = 0.06) (data not shown).
In stratified analysis by sex, HIV-positive participants with
a 25(OH)D serum level of < 20 ng/ml had a higher proportion
of high CRP (> 3mg/liter) of 42% and 23% in men and
women, respectively, compared with 19% and 12% in those
with a 25(OH)D serum level of ‡ 20 ng/ml in men and wo-
men, respectively. The overall significant protective effect of a
25(OH)D serum level of ‡ 20 ng/ml against inflammation
remained significant in men but not in women. In men, those
with a 25(OH)D serum level of < 20 ng/ml had a 3.2-fold
higher odds of high CRP (> 3mg/liter) compared to those
with a 25(OH)D serum level of ‡ 20 ng/ml ( p= 0.02). In
women, those with a 25(OH)D serum level of < 20 ng/ml had
a 2.7-fold higher odds of high CRP (> 3mg/liter) compared to
those with a 25(OH)D serum level of ‡ 20 ng/ml ( p= 0.28).
Although the difference was not statistically significant in
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women, the adjusted odds ratio was increased [2.67 (0.44–
15.96)]. The protective effect of a 25(OH)D serum level of
‡ 20 ng/ml against inflammation did not change in further
analysis after excluding participants with any history of dis-
ease in the past 12 months including minor illnesses or par-
ticipants without a history of antiretroviral medication (data
not shown).
In further stratified analysis by dividing vitamin D defi-
ciency into severe [25(OH)D serum levels of < 10 ng/ml] and
moderate [25(OH)D serum levels of 10–19.99 ng/ml], the
Table 1. Characteristics of HIV-Positive People with 25-Hydroxyvitamin D Levels
25-Hydroxyvitamin D
< 20 ng/ml ‡ 20 ng/ml p-valuea
Subjects (n) 263 53
Age (mean – sd, year) 34.2 – 6.91 35.0 – 7.90 0.47
Sex (men, %) 144 (54.75) 37 (69.81) 0.04
Marital status (married, %) 184 (69.96) 32 (60.38) 0.17
Education (never been to school, %) 50 (19.01) 8 (15.09) 0.50
Occupation (no work, %) 79 (30.04) 21 (39.62) 0.17
Smoking (never, %) 143 (54.37) 25 (47.17) 0.33
Alcohol consumption (never, %) 228 (86.69) 48 (90.57) 0.43
Duration of antiretroviral therapy (months, %)
Not taking antiretroviral medicine 63 (23.95) 23 (43.40)
0–12 62 (23.57) 12 (22.64)
13–24 47 (17.87) 6 (11.32)
25–36 36 (13.69) 6 (11.32)
> 36 55 (20.91) 6 (11.32) 0.05
History of any disease in past 12 months (yes, %) 165 (62.74) 35 (66.04) 0.64
Efavirenz exposure (yes, %) 57 (21.67) 8 (15.09) 0.27
Nevirapine exposure (yes, %) 126 (47.91) 20 (37.74) 0.17
Tenofovir exposure (yes, %) 5 (1.90) 1 (1.89) 0.99
Nucleoside reverse transcriptase inhibitor exposure (yes, %) 12 (4.56) 1 (1.89) 0.37
History of any disease in past 12 months (yes, %) 165 (62.74) 35 (66.04) 0.64
Body mass index (mean – sd, kg/m2) 21.55– 2.97 22.52– 2.81 0.03
Physical activity ( > 3.5, h/day) 132 (50.19) 23 (43.40) 0.37
Systolic blood pressure (mean – sd, mm Hg) 115.69 (20.34) 116.51 (25.31) 0.82
Cholesterol (mean – sd, mg/dl) 142.98 (44.18) 153.61 (41.17) 0.09
Triglycerides (median, range; mg/dl) 115 (44–791) 107 (24–1071) 0.62
CD4 + T cell count (median, range; cells/ll) 347 (60–1009) 349 (15–1551) 0.82
ap values were based on the Student’s t test for continuous variables and chi-square test for categorical variables.
Table 2. Odds Ratios and 95% CIs for High HS C-Reactive Protein (CRP> 3 mg/liter) According to
Serum 25-Hydroxyvitamin D Concentrations in HIV-Positive People
25-Hydroxyvitamin D
< 20 ng/ml ‡ 20 ng/ml p value
Serum 25-hydroxyvitamin D (median, ng/ml) 12.9 (3.48) 23.8 (3.62)
n with higher CRP 88/263 9/53
Univariate model OR (95% CI) 2.45 (1.15–5.26) 1.00 (ref) 0.02
Multivariate modela OR (95% CI) 3.19 (1.39–7.30) 1.00 (ref) 0.005
Men 12.6 (3.39) 25.0 (3.81)
n with higher CRP 60/144 7/37
Univariate model OR (95% CI) 3.06 (1.26–7.43) 1.00 (ref) 0.01
Multivariate modela OR (95% CI) 3.22 (1.19–8.67) 1.00 (ref) 0.02
Women 13.4 (3.56) 22.5 (2.47)
n with higher CRP 28/119 2/16
Univariate model OR (95% CI) 2.15 (0.46–10.05) 1.00 (ref) 0.33
Multivariate modela OR (95% CI) 2.67 (0.44–15.96) 1.00 (ref) 0.28
aAll multivariate models adjusted for age (years, continuous), sex (men or women), marital status (married or unmarried/separated),
education (never or ever been to school), occupation (yes or no), alcohol intake (never or ever), smoking (never or ever), physical activity
( £ 3.5 or > 3.5, h/day), body mass index (kg/m2, continuous), history of any disease including minor illnesses in past 12 months (yes or no),
systolic blood pressure (mmHg, continuous), cholesterol (mg/dl, continuous), triglycerides (mg/dl, continuous), CD4+ T cell count ( £ 200 or
> 200; cells/ll), and duration of antiretroviral therapy (no, 0–12, 13–24, 25–36, > 36 months), and efavirenz exposure (yes or no).
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HIV-positive participants with 25(OH)D serum levels of
< 10 ng/ml had an increased proportion of high CRP levels
(24/61 = 39.3%) than those HIV-positive participants with
25(OH)D serum levels of 10–19.99 ng/ml (64/202= 31.7%)
and ‡ 20 ng/ml (9/53 = 16.9%). The risk of having high CRP
was also increased inHIV-positive participants with 25(OH)D
serum levels of < 10 ng/ml. The multivariate-adjusted odds
ratios (95% confidence intervals) of having high CRP for HIV-
positive participantswith 25(OH)D serum levels of < 10ng/ml
and 10–19.99ng/ml as compared to HIV-positive participants
with 25(OH)D serum levels of ‡ 20 ng/ml were 4.00 (1.52–
10.55) and 2.99 (1.29–6.94), respectively ( p for trend = 0.007)
(data not shown).
Discussion
In our cohort of HIV-positive participants, we found
greater odds of having high inflammation (CRP > 3mg/liter)
among HIV-positive men and women with a 25(OH)D serum
level of < 20 ng/ml, although the relationship was not sig-
nificant in women. To our knowledge, this is the first study
exploring the association between 25(OH)D serum levels and
inflammatory markers among HIV-positive people.
We found that the risk of having high inflammation
(CRP > 3mg/liter) was greater among HIV-positive people
with a 25(OH)D serum level of < 20 ng/ml. We are unaware
of any similar studies reporting an association between
25(OH)D serum levels and inflammatory markers in HIV-
positive people for our comparison. However, our findings
are in line with those studies previously highlighting an in-
verse association between vitamin D and inflammatory
markers in different populations. For example, in a European
cohort of obese subjects, 25(OH)D serum concentrations were
inversely related to significant levels of high CRP, regardless
of the total quantity of fat mass.28 In another study among
patients with early inflammatory polyarthritis, each 10 ng/ml
increase in 25(OH)D serum level was associated with a 25%
decrease in serum CRP.19 In addition, two clinical trials have
suggested that vitamin D supplementation markedly reduces
serum levels of CRP and several other inflammation markers
in critically ill patients and patients with congestive heart
failure, respectively.29,30
We could not find any significant difference between the
ART exposure such as efavirenz and others and 25(OH)D
serum level of < 20 ng/ml/ ‡ 20 ng/ml among our partici-
pants. The relationship between serum CRP concentrations
and 25(OH)D serum level did not change in further adjust-
ments of efavirenz exposure in the multivariate model in our
study. An efavirenz intake has been shown to affect vitamin D
metabolism in HIV-positive adults in previous studies.31–33
The low 25(OH)D serum levels among overall participants
may be a reason for the lack of association between vitamin D
levels and efavirenz exposure in our study.
In our study, men and women with a 25(OH)D serum level
of < 20 ng/ml had a higher risk of high CRP ( > 3mg/liter).
Although the association in women did not reach statistical
significance, the odds ratio was increased after taking into
account other variables in the multivariate analysis.
The present findings supporting a protective role of
25(OH)D serum level of ‡ 20 ng/ml against inflammation can
be explained through the immunomodulating effects of vita-
min D referring to mechanistic studies.15 Vitamin D may act
as an immune modulator and interfere with systemic in-
flammation through the expression of nuclear vitamin D re-
ceptors in most cells of the immune system, including
activated CD4 and CD8 T lymphocytes, as well as macro-
phages.34,35 For example, some experimental studies have
suggested that vitamin D can exert regulatory effects on the
cytokine production of human peripheral blood lympho-
cytes35,36 and can also down-regulate the activation of nuclear
factor-jB, an important regulator of genes encoding for sev-
eral inflammatory cytokines.20
Some limitations of our study deserve comment. First,
the possibility of reverse causality must be considered,
namely that inflammation may influence the 25(OH)D se-
rum level, a possibility that the cross-sectional design of
our study prevents us from ruling out. It may be less likely
to influence our study result because we adjusted infor-
mation on past history of any disease including minor ill-
nesses over the past 12 months in the multivariate models
and also did further analysis excluding participants with
any history of disease including minor illnesses in the past
12 months. The protective effect of a 25(OH)D serum level
of ‡ 20 ng/ml against inflammation did not change in ei-
ther analysis. Though the past history of any disease in-
cluding minor illnesses was self-reported, we asked for
even mild illnesses so that it would not affect the study
result. In addition, our hypothesis that vitamin D defi-
ciency influences inflammation was based on previous
study findings including clinical trials.29,30 Second, al-
though we adjusted for factors known to influence serum
25(OH)D level and CRP level, the possibility of residual
confounding cannot be excluded. Finally, the conclusions
drawn from subgroup analysis might be due to chance, and
should thus be interpreted with caution.
In conclusion, the present study suggests that the risk of
having high inflammation (CRP > 3mg/liter) may be elevated
among HIV-positive people with a 25(OH)D serum level of
< 20 ng/ml. These findings are important in that they may
lead to potential new intervention strategies (e.g., supple-
mentation, dietary changes) to increase improved health and
quality of life for HIV-positive people. Further prospective
studies to confirm the role of vitamin D against inflammation
in HIV-positive people are warranted.
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